Benefits
Depression
The clearest study cited here is an 8 week randomized, double blind trial in 60 people newly diagnosed with a first episode of depression who were under medical care. It compared 5-HTP with the prescription antidepressant fluoxetine: 73.3 percent of the 5-HTP group and 80 percent of the fluoxetine group responded. There was no placebo group, so it is not possible to say how much of the improvement came from the treatment itself. This is a small drug comparison study with no placebo group. A separate placebo-controlled trial in Parkinson's disease (Meloni 2020) found 5-HTP improved depression scores versus placebo, and a meta-analysis of seven depression trials (Javelle 2020) reported a large pooled effect, though it rated the underlying studies as weak because few used placebo controls. None of this is evidence that a supplement lifts mood in healthy people. Depression needs professional care, and no one should start 5-HTP alongside, or in place of, prescribed medication.
Sleep Improvement
One cited trial tested sleep: a 12 week study in 30 older adults in Singapore (Sutanto 2024) that gave 100 mg/day 5-HTP or nothing. It reported better sleep scores in poor sleepers, but it had no placebo group, was only single blinded, and was small, so the result is preliminary. The body also turns serotonin into melatonin, which is why 5-HTP is often taken in the evening.
Fibromyalgia
One old trial is cited: a 1990 double blind, placebo controlled study in 50 people with primary fibromyalgia (Caruso) that reported improvement across pain, sleep and tender point measures on 100 mg three times daily. It is a single small study from one group and has not been replicated. Fibromyalgia is a diagnosed medical condition that needs a doctor's care, and this trial does not make 5-HTP a treatment for it.
Weight Management
One cited trial tested body composition: an 8 week randomized, placebo controlled study in 48 exercise trained adults (Evans 2023) using 100 mg/day of a branded 5-HTP. Fat mass fell in the 5-HTP group with a borderline between group difference (p=0.048), while lean mass, body water and food intake did not change. It was small, unevenly split (31 versus 17) and used bioelectrical impedance rather than a precise method, so treat weight claims cautiously.
Migraine Prophylaxis
One old trial is cited: a 1986 open label study in 124 people with migraine (Titus) comparing 5-HTP with the prescription drug methysergide, with no placebo group. A comparison against a prescription drug is not proof that 5-HTP prevents migraine. This is also a safety point: migraine medicines such as triptans raise serotonin, and combining them with 5-HTP can be dangerous. Talk to a doctor about migraine treatment instead.
Gut Health
One cited trial (Sutanto 2024, 30 older adults) measured gut bacteria and reported changes in microbial diversity and short chain fatty acid producing bacteria. This is a single small study with no placebo group, so it remains an early research idea only.
Mechanism of action
Neurotransmitter Modulation
Elevated serotonin levels enhance signaling through serotonin receptors (e.g., 5-HT1A, 5-HT2C), which are involved in mood regulation, anxiety reduction, and satiety. This is the proposed explanation for the effects people look for, but the only study cited here is a small depression trial in diagnosed patients, and no cited study tested fibromyalgia, weight or appetite. Serotonin made from 5-HTP is also the raw material for melatonin, which is why 5-HTP is often taken at night. No study cited on this page measured sleep onset or sleep quality.
Central and Peripheral Effects
Unlike serotonin, 5-HTP crosses the blood-brain barrier, increasing CNS serotonin synthesis. Peripherally, it may influence gut motility and microbiota by boosting serotonin in enterochromaffin cells, potentially affecting gut health.
Anti-Inflammatory and Pain Modulation
Serotonin is involved in the brain and spinal cord pathways that dampen pain signals, so raising it has been proposed as a way to change pain perception. This is theory only: no study cited on this page measured pain.
Appetite Suppression
5-HTP may act on serotonin receptors (such as 5-HT2C) in the hypothalamus, a brain region involved in fullness and cravings. This is a proposed mechanism only: no study cited on this page measured appetite, food intake or weight.
Clinical trials
Single-center, randomized, double-blind, placebo-controlled crossover trial in 25 patients with Parkinson's disease and depression/apathy. Patients received 50 mg/day 5-HTP or placebo for 4 weeks each, with assessments via Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory-II (BDI-II), and Apathy Scale (AS).
25 patients with Parkinson's disease. 4-week crossover.
In this 25 person crossover study in people with Parkinson's disease (Meloni 2020), 50 mg/day 5-HTP significantly improved depressive symptoms on the Hamilton Depression Rating Scale versus placebo, but did not change apathy. The authors called the finding preliminary and asked for larger, longer trials. Results in people with a neurological disease do not show what 5-HTP does for a healthy person.
Double-blind, placebo-controlled trial in 50 patients with primary fibromyalgia syndrome. Patients received 100 mg 5-HTP three times daily (300 mg/day) or placebo for 30 days. Outcomes: pain intensity, sleep quality, fatigue, and tender point count.
50 patients with primary fibromyalgia syndrome. 30-day intervention.
This is the 1990 Caruso trial, a 30 day double blind, placebo controlled study in 50 people diagnosed with fibromyalgia, in which all measured clinical parameters improved on 5-HTP versus placebo with only mild transient side effects. It is a single small study from one group and has not been replicated, and it was done in diagnosed patients under medical care, not in people without the condition.
Single-blinded, 12-week parallel randomized controlled trial in 30 older adults (mean 66 years) in Singapore. Participants received 100 mg/day 5-HTP or no supplementation. Sleep quality assessed via Pittsburgh Sleep Quality Index (PSQI) and actigraphy; serum serotonin, urine melatonin, and 16S gut microbiota also measured.
30 older adults (mean age 66). 12-week intervention.
This is the 2024 Sutanto trial. As reported, 5-HTP was linked to better sleep scores in poor sleepers, higher serum serotonin, and changes in gut microbiota α-diversity and SCFA-producing bacteria abundance. No significant adverse events were reported. Key limitations: there was no placebo, since the comparison group simply took nothing, and the study was only single blinded, so expectation alone could explain part of the sleep rating. Only 30 people took part, and the sleep benefit was seen in a smaller subgroup of poor sleepers, which makes it preliminary at best.
Randomized clinical trial in 124 migraine patients comparing 5-HTP (up to 300 mg/day) vs. methysergide (up to 6 mg/day). Outcomes: migraine frequency, intensity, and duration.
124 migraine patients. Open-label randomized comparison.
This is the 1986 Titus trial. It was an open label comparison, so everyone knew what they were taking and there was no placebo group, and it tested 5-HTP against a prescription migraine drug in people diagnosed with migraine. A comparison against a prescription drug is not evidence that a supplement prevents migraine, and the authors' wording should not be read as a reason to use 5-HTP instead of medical care.
Randomized, placebo-controlled, double-blind trial in 48 resistance-trained adults. Participants received 100 mg/day 5-HTP (CLEANMOOD™) or placebo (maltodextrin) for 8 weeks. Body composition assessed by multi-frequency bioelectrical impedance (InBody® 270).
48 resistance-trained adults (31 5-HTP, 17 placebo). 8-week intervention.
Fat mass decreased significantly in the 5-HTP group (p=0.02) but not in placebo (p=0.58); between-group difference was significant (p=0.048). Lean body mass, total body water and food intake did not change. This is the 2023 Evans trial using a branded 5-HTP (CLEANMOOD). It was small and unevenly split (31 people on 5-HTP versus 17 on placebo), body fat was estimated with bioelectrical impedance rather than a precise method, the between group difference was borderline, and it tested one branded 5-HTP product, so it does not automatically apply to other products.
Evidence review and pooled analysis (PRISMA-guided, PROSPERO pre-registered) of 13 studies in the evidence review and 7 in the pooled analysis assessing 5-HTP for depression. Doses ranged 50–600 mg/day across various depression types. (Nutrition Reviews)
13 investigations included; 7 in full pooled analysis.
Depression remission rate of 0.65 (95% CI: 0.55–0.78), with large Hedges' g=1.11 (95%CI: 0.53–1.69). Significant methodological variability (I²=76%) due to differences in treatment duration, depression type, design, and dosing. This is the 2020 Javelle meta-analysis in Nutrition Reviews. The studies it pooled were done in people diagnosed with depression and varied widely in dose, length and design, and the authors themselves said that variation prevents firm recommendations. It is not evidence that 5-HTP improves mood in healthy people, and depression should be treated by a clinician.